Echinacea Extract
Phase 2Small molecule
Echinacea Extract is one of 13 small molecule programs targeting Parasitic Infection. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Cryptosporidiosis
#DrugCompanyPhaseTrials
1Alinia
RRomark Laboratories L.C.
Phase 3
Lamprene
NovartisPhase 2
IL-12
PfizerPhase 2
Paromomycin Sulfate
PPATH
Phase 2
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Echinacea Extract
AAl-Azhar University
Phase 2
Interleukin-12
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Spiramycin
RRhone-Poulenc Rorer
Preclinical
Diclazuril
Johnson & JohnsonPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cryptosporidiosis1 trial
The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children
Recruiting·—·Phase 2·NCT07388615·60 enrolled
Parasitic Infection1 trial
Parasitic Infections and Ulcerative Colitis: Combining Anti-parasitic and Immunomodulatory Treatments May Achieve Remission
Completed·—·N/A·NCT06583863·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Echinacea Extract. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAl-Azhar University